Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gait Analysis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    48 result(s) found for: Gait Analysis. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2005-004685-17 Sponsor Protocol Number: ERA2005neuro Start Date*: 2005-11-16
    Sponsor Name:CUB - Hôpital Erasme
    Full Title: A prospective placebo controlled study of botulilium toxin (BOTOX) on gait disorder induced by spastic equinovarus foot.
    Medical condition: Spastic equinus foot is a common dynamic deformity in patients with cerebral palsy. This dynamic deformity, mainly caused by spasticity of the soleus, gastrocnemius and tibialis posterior muscles, ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000403-32 Sponsor Protocol Number: LIDrfvm001 Start Date*: 2019-07-23
    Sponsor Name:Roessingh Research and Development
    Full Title: The effect of lidocaïne injections in the m. vastus intermedius and the m. rectus femoris on the gait pattern in patients walking with stiff knee gait after a stroke.
    Medical condition: Patients walking with stiff knee gait after a stroke
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001218-40 Sponsor Protocol Number: SC12-02 Start Date*: 2012-05-21
    Sponsor Name:FONDAZIONE SANTA LUCIA
    Full Title: EFFICACY OF ROTIGOTINE ON GAIT PERFORMANCE OF PARKINSONIAN PATIENTS
    Medical condition: Patients suffering for Idiopathic Parkinson’s Disease. H&Y stage > or = 2 with un-satisfactory control by on-going pharmacological therapy (Levodopa, COMT & MAO-inhibitors), characterised by an in...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10056242 Parkinsonian gait PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004474-42 Sponsor Protocol Number: V3_06082015 Start Date*: 2015-05-07
    Sponsor Name:Copenhagen University Hospital at Hvidovre
    Full Title: Treatment of equinus gait caused by dynamic tightening of the calf muscles in children with cerebral palsy. A randomized, placebo controlled Botulinum toxin type A volume/response study.
    Medical condition: Treatment of equinus gait caused by dynamic tightening of the calf muscles in children with cerebral palsy.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10015112 Equinus deformity of foot, acquired LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005076-34 Sponsor Protocol Number: BEL-FMP-12-10325 Start Date*: 2013-01-03
    Sponsor Name:Cliniques Universitaires Saint-Luc, Neurologie
    Full Title: Prolonged-release oral Fampridine in Multiple Sclerosis: effects on clinical, neurophysiological and quantified gait analysis parameters. A cross-over, double-blinded, placebo-controlled study.
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005312-26 Sponsor Protocol Number: FACEG Start Date*: 2013-03-18
    Sponsor Name:Hospital of the University of Munich, Grosshadern
    Full Title: Sustained release 4-aminopyridine (Fampyra®) in cerebellar gait disorder
    Medical condition: cerebellar gait disorder, cerebellar ataxia, sensorimotor adaption and ocular motor disorders, postural sway, dysarthria
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10008025 Cerebellar ataxia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005874-11 Sponsor Protocol Number: 0822-035 Start Date*: 2009-02-24
    Sponsor Name:Laboratoires Merck Sharp & Dhome-Chibret
    Full Title: A Substudy to Explore Biomarkers of Physical Function in the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of ...
    Medical condition: This is an exploratory sub-study of Protocol 018 (Eudract N°2007-002693-66) to identify biomarkers of physical function. This biomarker sub-study will use an ongoing clinical study (Protocol 018) ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031283 Osteoporosis fracture LLT
    9.1 10031285 Osteoporosis postmenopausal LLT
    Population Age: Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-000460-34 Sponsor Protocol Number: ALCAT Start Date*: 2015-11-18
    Sponsor Name:Hospital of the University of Munich
    Full Title: Effects of Acetyl-DL-Leucine on cerebellar ataxia - a multinational, multicenter, randomized, double-blind, placebo-controlled, 2-way crossover phase III trial (ALCAT)
    Medical condition: Cerebellar ataxia is a form of ataxia originating in the cerebellum and is most often caused by neurodegenerative disorders of the cerebellum, either hereditary or sporadic. The leading clinical sy...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003574-66 Sponsor Protocol Number: 34964 Start Date*: 2013-01-04
    Sponsor Name:Ortopædkirurgisk Forskning - Aarhus Universitetshospita
    Full Title: Osseointegrated transdermal femoral amputation prostheses - Denusomab Trial
    Medical condition: leg amputee
    Disease: Version SOC Term Classification Code Term Level
    16.0 10042613 - Surgical and medical procedures 10024124 Leg amputation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002499-42 Sponsor Protocol Number: Version1on02-02-2018 Start Date*: 2018-08-29
    Sponsor Name:Cliniques Universitaires Saint-Luc
    Full Title: Evaluation of the effect of repeated injections of high doses of botulinum toxin into the lower limb of spastic brain lesions on functional and biomechanical parameters of walking
    Medical condition: Patients with spastic brain lesions. Children with cerebral palsy (CP) and in the hemiplegic adult.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004132-22 Sponsor Protocol Number: NPH-01 Start Date*: 2021-01-20
    Sponsor Name:Uppsala University Hospital
    Full Title: Double-blind randomized acetazolamide trial in normal pressure hydrocephalus
    Medical condition: Normal pressure hydrocephalus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10020510 Hydrocephalus acquired LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001116-65 Sponsor Protocol Number: B3D-MC-GHDQ Start Date*: 2012-02-10
    Sponsor Name:Eli Lilly and Company
    Full Title: Second study on the Effect of Teriparatide on Femoral Neck Fracture Healing
    Medical condition: Low trauma femoral neck fracture
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004863 10068399 Trochanteric femoral fracture LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) GR (Completed) PL (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021395-28 Sponsor Protocol Number: B3D-MC-GHDN Start Date*: 2012-04-03
    Sponsor Name:Eli Lilly and Company
    Full Title: Effect of Teriparatide on Femoral Neck Fracture Healing
    Medical condition: Low trauma femoral neck fracture
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022117 - Injury, poisoning and procedural complications 10016450 Femoral neck fracture PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) LV (Completed) FI (Completed) NO (Completed) LT (Completed) EE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-004650-34 Sponsor Protocol Number: GR-2011-02348985 Start Date*: 2016-06-27
    Sponsor Name:IRCCS FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE C. MONDINO
    Full Title: Neuromodulation strategies to enhance the effects of gait rehabilitation in multiple sclerosis patients with cerebellar ataxia
    Medical condition: Multiple sclerosis with cerebellar ataxia
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001725-75 Sponsor Protocol Number: 2015-DFU-301 Start Date*: 2018-12-12
    Sponsor Name:FirstString Research, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Parallel-group, Vehicle controlled, Multicenter Study of the Efficacy and Safety of Granexin Gel in the Treatment of Diabetic Foot Ulcer (GAIT 1)
    Medical condition: Diabetic Foot Ulcer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-003287-18 Sponsor Protocol Number: PET-FRAX-001 Start Date*: 2008-09-17
    Sponsor Name:University Antwerp [...]
    1. University Antwerp
    2. University Hospital Leuven gasthuisberg
    Full Title: Functional consequences of decreased RNA expression of certain GABA(A) receptor subunits in fragile X patients using Positron Emission Tomography and [11C]flumazenil.
    Medical condition: Fragile X syndrome is the most common form of inherited mental retardation with a prevalence of 1/4000 males and 1/6000 females. Patients are characterized by a mild to severe form of cognitive imp...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018412-32 Sponsor Protocol Number: DMD114117 Start Date*: 2010-08-05
    Sponsor Name:GlaxoSmithKline Research and Development LTD
    Full Title: A phase II, double blind, exploratory, parallel-group, placebo-controlled clinical study to assess two dosing regimens of GSK2402968 for efficacy, safety, tolerability and pharmacokinetics in ambul...
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) NL (Completed) FR (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-011541-24 Sponsor Protocol Number: TVP-1012/501 Start Date*: 2009-10-09
    Sponsor Name:Teva Pharmaceutical Industries Ltd
    Full Title: An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) HU (Completed) FR (Completed) ES (Completed) IT (Completed) DE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000107-17 Sponsor Protocol Number: EAT2TREAT Start Date*: 2013-05-22
    Sponsor Name:Hospital of the University of Munich, Grosshadern
    Full Title: Pharmacological therapy of episodic ataxia type 2: a placebo-controlled comparison of the efficacy of 4-aminopyridine sustained-release (Fampyra TM) and acetazolamide (Acemit TM)
    Medical condition: Familial episodic ataxia (EA) represents a genetically and phenotypically diverse group of rare autosomal dominant hereditary disorders characterized by episodes of imbalance and incoordination tha...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10067447 Episodic ataxia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002383-95 Sponsor Protocol Number: 0773-005-00 Start Date*: 2007-08-08
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0773 in Patients with Sarcopenia
    Medical condition: Sarcopenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063024 Sarcopenia LLT
    Population Age: Elderly Gender: Female
    Trial protocol: DK (Completed) ES (Completed) FR (Completed) GB (Completed) FI (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:06:18 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA